CME Lunch Symposium
A Closer Look at CV Outcomes for Type 2 Diabetes Therapies: Implications for Patient Care
Thursday, October 22, 2015
11:45am –1:45pm
Supported by an educational grant from Merck & Co., Inc.

SYMPOSIUM OVERVIEW
Patients with type 2 diabetes mellitus are at risk for cardiovascular disease and reducing this risk is a desirable outcome of therapy. Conflicting research on the CV benefits of glucose lowering and the safety of diabetes therapies have led to questions in the medical community. The pursuit of accurate glycemic control and of other CV risk factors may be needed to reduce risk. In this symposium, faculty will examine the latest evidence evaluating the CV outcomes of newer diabetes therapies in relation to potential risks and benefits. Case studies will demonstrate how to integrate these new data into clinical practice.

LEARNING OBJECTIVES
Upon completion of this educational activity, participants will be better able to:
- Examine the epidemiologic data establishing an increased risk for cardiovascular events in patients with type 2 diabetes.
- Explain the rationale for FDA guidance requiring CV safety studies for new diabetes treatments
- Evaluate the available results from CV outcomes studies of newer diabetes therapies and discuss their potential clinical implications.

AGENDA & FACULTY

Welcome and Introductions
Chairperson: Jay S. Skyler, MD

CV Outcomes for Type 2 Diabetes Therapies: How Did We Get Here?
Presenter: Deepak L. Bhatt, MD, MPH

Cardiovascular Safety of Antihyperglycemic Agents in Type 2 Diabetes
Presenter: Jennifer B. Green, MD

Balancing Risk and Benefit: Therapeutic Approaches for Clinical Benefit
Presenter: Darren K. McGuire, MD, MHSc

Expert Roundtable & Interactive Panel Discussion: Implications for Patient Care
Moderator: Jay S. Skyler, MD
Discussants: Deepak L. Bhatt, MD, MPH; Jennifer B. Green, MD; Darren K. McGuire, MD, MHSc

Summary and Closing Remarks
Chairperson: Jay S. Skyler, MD

Note: Agenda & Faculty are subject to change.